Srini Ramanathan, Ph.D., is the Chief Development Officer at Roivant responsible for asset diligence, intake and stand-up of new biotechnology companies (“vants”) in the Roivant portfolio. He is a veteran in the biotechnology industry with several drug approvals spanning immunology, oncology and virology. Dr. Ramanathan was previously at Horizon Therapeutics, where he was Senior Vice President of Research and Development Sciences, with portfolio oversight of discovery research and various functions supporting preclinical and clinical development, and scientific aspects of business development. Before joining Horizon, Dr. Ramanathan served as Senior Project Leader at AbbVie, overseeing the development of multiple immunology programs for rheumatology and gastrointestinal indications. Prior to AbbVie, he served as Global Head of Clinical Pharmacology at Gilead Sciences with portfolio responsibilities across all therapeutic areas.